SCHEMBL13645914

SCHEMBL13645914

COC(=O)c1ccc(F)c(C2CCNCC2)c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRNB2 P17787 1/20 0.44
CHRNA4 P43681 1/20 0.44
SLC6A3 Q01959 4/20 0.42
SLC6A2 P23975 3/20 0.42
SLC6A4 P31645 3/20 0.42
HTR1A P08908 1/20 0.42
CA12 O43570 1/20 0.41
CA1 P00915 1/20 0.41
CA2 P00918 1/20 0.41
CA7 P43166 1/20 0.41
XDH P47989 1/20 0.41
CA9 Q16790 1/20 0.41
CA14 Q9ULX7 1/20 0.41
OPRD1 P41143 1/20 0.40
HTR2C P28335 2/20 0.40
TLR9 Q9NR96 1/20 0.40
TLR8 Q9NR97 1/20 0.40
KDM4E B2RXH2 1/20 0.40
ALDH1A1 P00352 1/20 0.40
PLAT P00750 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL3861904 0.99 CHRNB2 (0.43) CHRNB2CHRNA4SLC6A3SLC6A2SLC6A4
SCHEMBL31435251 0.90 SLC6A3 (0.47) CHRNB2CHRNA4SLC6A3SLC6A2SLC6A4
SCHEMBL13646074 0.84 HTR2C (0.47) CHRNB2CHRNA4SLC6A3SLC6A2SLC6A4
SCHEMBL13646084 0.82 P2RY14 (0.41) SLC6A3SLC6A2SLC6A4HTR1AMEN1
SCHEMBL5321644 0.81 JAK2 (0.47) SLC6A3SLC6A2SLC6A4HTR1AHTR2C
SCHEMBL1763854 0.80 RBP4 (0.55) CHRNB2CHRNA4SLC6A3SLC6A2SLC6A4
SCHEMBL17397553 0.80 CHRNB2 (0.46) CHRNB2CHRNA4SLC6A3SLC6A2SLC6A4
SCHEMBL5325602 0.78 NMT2 (0.43) SLC6A3SLC6A2SLC6A4HTR1A
SCHEMBL31702082 0.78 POLB (0.42) CHRNB2CHRNA4SLC6A3SLC6A2SLC6A4
SCHEMBL25953851 0.78 CA12 (0.46) CHRNB2CHRNA4SLC6A3SLC6A2SLC6A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7598243-B2 inhibit atherosclerotic lesion formation and pathological progression by impairing monocyte recruitment and differentiation in the arterial wall; antiinflammatory, anticarcinogenic agent; autoimmune diseases MERCK & CO., INC. (US) 2009-10-06 US disclosed
US-7598243-B2 inhibit atherosclerotic lesion formation and pathological progression by impairing monocyte recruitment and differentiation in the arterial wall; antiinflammatory, anticarcinogenic agent; autoimmune diseases MERCK & CO., INC. (US) 2009-10-06 US disclosed
US-20080081803-A1 Heterocyclic cyclopentyl tetrahydroisoquinoline and tetrahydropyridopyridine modulators of chemokine receptor activity MERCK SHARP & DOHME CORP. 2008-04-03 US disclosed
US-20080081803-A1 Heterocyclic cyclopentyl tetrahydroisoquinoline and tetrahydropyridopyridine modulators of chemokine receptor activity MERCK SHARP & DOHME CORP. 2008-04-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080081803-A1 Heterocyclic cyclopentyl tetrahydroisoquinoline and tetrahydropyridopyridine modulators of chemokine receptor activity CCR1, CCR5, CCR2 CHRNB2 490/4885CHRNA4 269/4885SLC6A3 4370/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.